Cancer patients with blood clots — which occur in one of every 200 cancer patients and are the second most common cause of death among cancer patients — gain no benefit from the insertion of an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux (Arixtra), according to new research.